Latest Breaking News On - Mai xiaodan - Page 1 : comparemela.com

Analysis shows the rate of use with the originator biologic has decreased from 90% in 2016, to 19% in 2021.

United statesHerceptin biosimilarMai xiaodanTrastuzumab biosimilarBiologics biosimilars collective intelligence consortiumHarvard pilgrim health care instituteDrug administrationInternational conference on pharmacoepidemiologyHarvard medical schoolInternational conferenceTherapeutic risk managementAnnual meetingBiosimilars collective intelligence consortiumThird herceptinPublished januaryBreast cancer